Scalper1 News
BioMarin Pharmaceutical (BMRN) said Thursday that the FDA had rejected its Duchenne muscular dystrophy (DMD) drug Kyndrisa, saying the evidence for its effectiveness was inadequate. The news was not a surprise, as Kyndrisa (also known as drisapersen) had failed its clinical trials, leaving BioMarin to argue that the totality of the evidence supported the drug’s efficacy even though it didn’t hit the preset endpoints. The FDA called an advisory Scalper1 News
Scalper1 News